Contraindications to receiving BEXSERO meningococcal group B vaccine documented in Novartis Vaccines and Diagnostics (GlaxoSmithKline) package insert include:
- Individuals who experienced hypersensitivity or a severe allergic reaction after a previous dose of BEXSERO or to any ingredient found in the vaccine.
Persons with a latex sensitivity may be at greater risk for an allergic reaction if they receive a dose of BEXSERO from prefilled syringes as the tip caps of prefilled syringes contain natural rubber latex.
There are no well-controlled or adequate studies on the use of BEXSERO vaccine in pregnant women and no available data on the impact of BEXSERO vaccine on breastfeeding infants or on human milk excretion and production.
BEXSERO vaccine is approved for use in persons 10 through 25 years of age. BEXSERO vaccine is not approved for use in children younger than aged 10 or in adults older than 25 years.
Contraindications to receiving TRUMENBA meningococcal group B vaccine documented in Wyeth Pharmaceutical (Pfizer) package insert include a severe allergic reaction after a previous dose of TRUMENBA.
There are no well-controlled or adequate studies on the use of TRUMENBA in pregnant women and no available data on the impact of TRUMENBA vaccine on breastfeeding infants or on human milk excretion and production.
TRUMENBA vaccine is approved for use in persons 10 through 25 years of age. TRUMENBA vaccine is not approved for use in children younger than 10 years or in adults older than 25 years. The safety and effectiveness of TRUMENBA has not been evaluated in children under the age of 10 or in adults over the age of 65.
